We thus reasoned that should the same occur in advanced‐phase CML, then MDM2, which is physiologically responsible for p53 ubiquitination,32 might also target SETD2. This evidence concerns the gene TP53 and chronic myelogenous leukemia, BCR-ABL1 positive.